Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes
Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.